Chelidonium majus 30C and 200C in induced hepato-toxicity in rats

Introduction: Homeopathy is a popular form of complementary and alternative medicine and is used to treat for certain liver ailments.

Aim: To analyze the efficacy of homeopathic Chelidonium majus (Chel) 30C and 200C in amelioration of experimentally induced hepato-toxicity in rats.

Methods: Rats were randomized into six sub-groups: negative control; negative control+EtOH; positive control; positive control+EtOH group; Chel 30; Chel 200. Rats were sacrificed at day 30, 60, 90 and 120; various toxicity biomarkers and pathological parameters were evaluated. Gelatin zymography for determination of metalloproteinases activity and Western blot of p53 and Bcl-2 proteins were also employed. All analyses were observer blind.

Results: Chronic feeding of p-dimethyl amino azo benzene (p-DAB) and phenobarbital (PB) elevated the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), triglyceride, cholesterol, creatinine and bilirubin and lowered the levels of glutathione (GSH), glucose-6-phosphate dehydrogenase (G-6-PD), catalase and HDL-cholesterol. There were statistically significant modulations of these parameters in the treated animals, compared to positive controls. In both treated groups, there was downregulation of metalloproteinases, p53 and Bcl-2 proteins compared to over-expression in the positive control groups.

Conclusion: Both the potencies of Chel exhibited anti-tumor and anti-oxidative stress potential against artificially induced hepatic tumors and hepato-toxicity in rats. More studies are warranted.

Keywords

Hepato-toxicity - Homeopathy - Amelioration - Toxicity biomarkers - Immunodetection

• References

• 1 Rosser C. Homeopathy in cancer care: part 1 – an introduction to “like curing like”. Clin J Oncol Nurs 2004; 8 (03) 324-326.
• 2 Milazzo S., Russell N., Ernest E. Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer 2006; 42 (03) 282-289.
• 3 Downer S.M., Cody M.M., McCluskey P. et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. Br Med J 1994; 309: 86-89.
• 4 Colombo M.L., Bosisio E. Pharmacological activities of Chelidonium majus L. Pharmacol Res 1996; 33: 127-134.
• 5 Furusawa E., Furusawa S., Kroposki M., Cutting W. Higher plants as a source of antiviral agents. Prog Antimicrob Anticancer Chemother 1970; 2: 810-817.
• 6 Lozyuk L.V. Antiviral properties of some compounds of plant origin. Mikrobiol Zh (Kiev) 1977; 39: 343-348.
• 7 Sethi M.L. Screening of benzophenanthridine alkaloids for their inhibition of reverse transcriptase activity and preliminary report on the structure-activity relationships. Can J Pharm Sci 1981; 16: 29-34.
• 8 Horvath J., Kery A., Kulcsar G., Dan P., Nasz J. Antiviral effect of Chelidonium extracts. Proc Int Congr Chemother 1983; 9: 106-124.
• 9 Kery R.Y., Horvath J., Nasz I., Verzar-Petri G., Kulcsar G., Dan P. Antiviral alkaloid in Chelidonium majus L. Acta Pharm Hung 1987; 57: 19-25.
• 10 Boericke W. Pocket Manual of Homeopathic Meteria Medica. Indian edn. Calcutta: Sett Dey and Co.; 1976.
• 11 Clarke J.H. New Delhi: Jain Publishers and Co.; A Dictionary of Practical Materia Medica . Vol. I. 1978.
• 12 Gebhardt R. Antioxidative, antiproliferative and biochemical effects in HepG2 cells of a homeopathic remedy and its constituent plant tinctures tested separately or in combination. Arzneimittelforschung 2003; 53 (12) 823-830.
• 13 Riley D. Contemporary homoeopathic drug provings. J Am Inst Homeopath 1994; 87: 161-165.
• 14 Biswas S.J., Khuda-Bukhsh A.R. Effect of homeopathic drug, Chelidonium, in amelioration of p-DAB induced hepatocarcinogenesis in mice. BMC Complement Altern Med 2002; 2: 4-12.
• 15 Biswas S.J., Bhattacharjee N., Khuda-Bukhsh A.R. Efficacy of a plant extract (Chelidonium majus L.) in combating induced hepatocarcinogenesis in mice. Food Chem Toxicol 2008; 46 (05) 1474-1487.
• 16 Biswas S.J., Khuda-Bukhsh A.R. Cytotoxic and genotoxic effects of the azodye p-dimethylaminoazobenzene in mice: a time course study. Mutat Res 2005; 587: 1-8.
• 17 International Agency for Research on Cancer (IARC). IARC monographs program on the evaluation of carcinogenic risks to human. Lyons. Available at http://193.51.164.11/default/html 2003
• 18 Khuda-Bukhsh A.R. Towards understanding molecular mechanisms of action of homeopathic drugs: an overview. Mol Cell Biochem 2003; 253: 339-345.
• 19 Khuda-Bukhsh A.R. Laboratory Research in Homeopathy: Pro. Integr Cancer Ther 2006; 5 (04) 1-13.
• 20 Pathak S., Khuda-Bukhsh A.R. Assessment of hepatocellular damage and hematological alterations in mice chronically fed p-dimethylaminoazobenzene and phenobarbital. Exp Mol Pathol 2007; 83 (01) 104-111.
• 21 Pathak S., Das J.K., Biswas S.J., Khuda-Bukhsh A.R. Protective potentials of a potentized homeopathic drug, Lycopodium-30, in ameliorating azo dye induced hepatocarcinogenesis in mice. Mol Cell Biochem 2006; 258: 121-131.
• 22 Gay R.J., Mccomb R.B., Browers G.N. Optimum reaction conditions for human lactate dehydrogenase isoenzymes as they affect total lactate dehydrogenase activity. Clin Chem 1968; 14: 740-753.
• 23 Szasz G. Reaction rate method for gamma-glutamyl transferase activity in serum. Clin Chem 1976; 22: 2051-2055.
• 24 Chance B., Maehly A.C. Assay of catalase and peroxidase. Meth Enzymol 1955; 2: 764-775.
• 25 Billings P.C., Habres J.M., Liao D.C., Tuttle S.W. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman–Birk protease inhibitor. Cancer Res 1991; 51: 5539-5543.
• 26 Magi B., Bini L., Marzocchi B., Liberatori S., Raggiaschi R., Pallini V. Immunoaffinity identification of 2-DE separated proteins. In: Andrew J.L. 2-D Proteome Analysis Protocols. Methods in Molecular Biology. Vol. 112. 1999. New Jersey: Humana Press; 313-318.
• 27 Fisher R.A., Yates F. Statistical Tables for Biological, Agricultural and Medical Research. 4th edn. Edinburgh: Oliver and Boyd; 1953.
• 28 Biswas S.J., Pathak S., Khuda-Bukhsh A.R. Assessment of the genotoxic and cytotoxic potential of an anti-epileptic drug, phenobarbital, in mice: a time course study. Mutat Res 2004; 563: 1-11.
• 29 Plaa G.L., Amdun A.M., Doull J., Klasser C.D. Toxic responses of the liver. 4th edn. Pergamon Press; 1991.
• 30 Timbrell J.A. Principles of biochemical toxicology. London: Taylor and Francis; 1991.
• 31 Vinitha R., Thangaraju M., Sachdanandam P. Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. Jpn J Med Sci Biol 1995; 48: 145-156.
• 32 Bain P.J., Latimer K.S., Mahaffey E.A., Prasse K.W. Duncan and Prasse’s veterinary medicine, liver clinical pathology. 4th edn. Ames: Iowa State Press; 2003. pp. 193–214.
• 33 Valentine B.A., Blue J.T., Shelley S.M., Cooper B.J. Increased serum alanine aminotransferases activity associated with muscle necrosis in the dog. J Vet Intern Med 1990; 4 (03) 140-143.
• 34 Stockham S.L., Scott M.A. Fundamentals of veterinary clinical pathology. Ames: Iowa State University Press; 2002. pp. 434–459.
• 35 Khuda-Bukhsh A.R. Potentized homeopathic drugs act through regulation of gene-expression: a hypothesis to explain their mechanism and pathways of action in vivo . Complement Ther Med 1997; 5: 43-46.
• 36 De Oliveira C.C., De Oliveira S.M., Goes V.M., Probst C.M., Kreiger M.A., Buchi D.F. Gene expression profiling of macrophages following mice treatment with an immunomodulator medication. J Cell Biochem 2008; 104 (04) 1364-1377.
• 37 Hughes S.L., Smith A.C., Relton C. Homeopathy service in an NHS hospital breast cancer clinic: outcome study. Breast Cancer Res 2008 10.1186/bcr1977.
• 38 Jonas W.B., Gaddipati J.P., Rajeshkumar N.V. et al. Can homeopathic treatment slow prostate cancer growth?. Integr Cancer Ther 2006; 5 (04) 343-349.